Multaq (Dronedarone)

Dronedarone, the active ingredient in Multaq, is a Class III antiarrhythmic presented as a 400 mg tablet for oral use. It is employed to maintain sinus rhythm in adults with atrial fibrillation or atrial flutter, helping to reduce recurrence of these arrhythmias.

GNH USA supplies Multaq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other regulated markets. The company adheres to stringent quality standards and provides regulatory documentation for global procurement.

Multaq (dronedarone) is used in the management of cardiac rhythm disorders, specifically atrial arrhythmias.

Atrial fibrillation: helps maintain sinus rhythm and reduces recurrence of episodes. Atrial flutter: used to sustain normal rhythm after cardioversion or to prevent recurrence. Paroxysmal atrial fibrillation: supports rhythm control in patients with intermittent episodes.

Dronedarone may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Fatigue - Dizziness - Headache

Serious or Rare Side Effects: - Severe liver injury (hepatitis, hepatic failure) - Pulmonary toxicity (interstitial lung disease) - QT interval prolongation leading to torsades de pointes - Heart failure exacerbation - Severe skin reactions (Stevens‑Johnson syndrome)

Before initiating dronedarone, several safety considerations should be evaluated.

Contraindication in severe heart failure: avoid use in patients with NYHA class III/IV heart failure. Monitor liver function: obtain baseline hepatic enzymes and repeat periodically during therapy. Avoid in permanent atrial fibrillation: drug is not indicated for patients with continuous AF. Drug interactions: review concomitant medications, especially strong CYP3A4 inhibitors. Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Dronedarone interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, HIV protease inhibitors): may increase dronedarone exposure and toxicity. - Digoxin: dronedarone raises digoxin levels, risking toxicity. - Amiodarone: combined use increases risk of pulmonary and hepatic adverse effects.

Moderate Interactions (Monitor Closely): - Diltiazem or verapamil: may enhance dronedarone’s effect on cardiac conduction. - Warfarin: dronedarone can elevate INR, requiring closer anticoagulation monitoring. - Statins metabolised by CYP3A4 (e.g., simvastatin, atorvastatin): may increase statin concentrations, monitor for myopathy.